BresMed is proud to sponsor the annual research award from the Dutch Association for Health Technology Assessment (NVTAG).
The NVTAG prize is awarded to a promising young researcher every year to recognize a published manuscript that contributes to the development of health technology assessment (HTA) research methods in an original manner.
Congratulations to Stefan Lipman for winning this year’s NVTAG young researcher award!
The shortlisted researchers for this year’s award were:
Mohamed El Alili
“Taking the analysis of trial-based economic evaluations to the next level: the importance of accounting for clustering”
“Simulating Progression Free and Overall Survival for First Line Doublet Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients Based on Real World Registry Data”
“QALYs without bias? Nonparametric correction of time trade‐off and standard gamble weights based on prospect theory”
Nick Sullivan, BresMed CEO commented, “We are very proud to be sponsoring this award in recognition of promising new researchers in our field. The Netherlands is an important market for us, we have a growing team who have been based in Utrecht since 2014 and we are strong supporters of NVTAG and its work bringing stakeholders together and innovating in health economics.”
The Dutch Association for Health Technology Assessment (NVTAG) was founded in 1995 and is the platform in the Netherlands for anybody with an interest in assessment of medical technologies. The NVTAG stimulates research and education related to evaluation of medical, social and economic effects of health technologies. By doing this, the NVTAG promotes efficient use of these technologies. The association aims to contribute to the quality and implementation of such research.